Back to News
Market Impact: 0.15
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
YOL104-2 is described as a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic. It has the potential to be a first-in-class therapy for ocular surface squamous neoplasia (OSSN); no clinical results or development milestones are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- ‘I don’t care how it’s done’: Trump pressures Ukraine to cut peace deal
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally
- Australian AI data centre operator NextDC shares shed 44% on revenue delay
- SpaceX posts first operating profit as public company as AI revenue nearly triples to $7.6 billion—cruising past Starlink
- SpaceX says big AI growth fueled revenue jump
- A top medical technology stock is trading at a big discount. Here's why I'm buying
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide